Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Eli Lilly and Company
Hoffmann-La Roche
Norwegian University of Science and Technology
Tesaro, Inc.
Mario Negri Institute for Pharmacological Research
Spanish Lung Cancer Group
Centus Biotherapeutics Limited
AbbVie
Amgen